Highest-materiality recent filing
MoonLake Phase 3 IZAR-1 meets all endpoints; Q2 cash $537M, runway to mid-2028
IZAR-1 Week 16: ACR50 42.1%, ACR20 66.5%, MDA 41.2%, PASI90 61% for sonelokimab 60mg.
MoonLake Immunotherapeutics raises additional $30M from underwriters' overallotment exercise
Underwriters exercised in full their option to purchase 1,500,000 additional ordinary shares.
MoonLake Immunotherapeutics launches $200M public offering of 9M shares at $20.00 each
Offering consists of 9,000,000 Class A ordinary shares at $20.00/share plus pre-funded warrants for up to 1,000,000 shares at $19.9999 each.
MoonLake Phase 3 VELA Week 52: 67% HiSCR75, 33% HiSCR100; BLA submission end-Sept 2026
Across VELA-1/2, 67.2% of SLK-treated patients achieved HiSCR75, 33.1% HiSCR100 at Week 52 (n=396).
MoonLake shareholders approve 5M share increase to equity plan at 2026 AGM
Shareholders approved amendment to 2022 Equity Incentive Plan, adding 5,000,000 Class A shares for awards.
Master Commercial Supply Agreement signed May 22, 2026 with Vetter for manufacturing pre-filled application systems.
MoonLake aligns with FDA on BLA for sonelokimab in HS; Q1 cash $357.9M
FDA pre-BLA meeting positive; alignment on submission plans, adolescent data inclusion, and safety strategy.
Phase 2 S-OLARIS trial: 81% of SLK-treated patients achieved ASAS40 response at Week 12 (n=26, mNRI).
MoonLake gets FDA clarity on SLK in HS; no new trials needed for BLA submission
FDA confirms MoonLake can establish substantial evidence of effectiveness using existing VELA-1, VELA-2, and MIRA trials; no additional HS trials required.
MoonLake Immunotherapeutics raises $75M in equity offering of 7.1M shares at $10.50/share
Offering of 7,142,857 Class A ordinary shares at $10.50 per share for gross proceeds of $75M.
MoonLake Q3 2025: $380.5M cash, positive Phase 2 PPP data for Sonelokimab
Cash and equivalents $380.5M as of Sept 30, 2025; runway into H2 2027.
VELA-1 achieved HiSCR75 at week 16 with 34.8% vs 17.5% placebo, delta 17.3% (p<0.001).
MoonLake Q2 cash $425M; Phase 3 HS readout expected Sept 2025
R&D expenses Q2 $49.8M (up from $36.5M Q1) on trial ramp-up and BLA preparation.
MoonLake shareholders elect all director nominees and approve auditor and say-on-pay at AGM
All three Class III director nominees elected: Dr. Jorge Santos da Silva, Simon Sturge, Dr. Andrew Phillips with over 53M votes for each.
Cash, cash equivalents and short-term marketable debt securities of $480.1M as of March 31, 2025.
MoonLake to post investor presentation for Capital Markets Day; no specific figures disclosed
MoonLake Immunotherapeutics will post an investor presentation for its Capital Markets Day on April 29, 2025.
MoonLake secures up to $500M non-dilutive loan from Hercules Capital; $75M drawn at close
Up to $500M non-dilutive term loan facility from Hercules Capital; $75M funded at close on March 31, 2025.
MoonLake reports FY 2024 net loss of $121.2M, cash of $448M; advances sonelokimab to Phase 3
Net loss for 2024 was $121.2M, compared to $44.1M in 2023, driven by increased R&D spending.
MoonLake director resigns; CEO, CSO, CFO each to receive $4M equity grants in Jan 2025
Dr. Kara Lassen resigns from Board effective Dec 31, 2024, due to new role at Roche Pharma; no dispute with Company.
MoonLake Q3 cash $493.9M; Phase 3 HS readout on track for mid-2025
Cash, equivalents and short-term debt securities of $493.9M as of Sep 30; runway to end of 2026.
Investor presentation covers financial position, near-term catalysts, and publication roadmap.
Q2 2024 cash, equivalents and short-term debt securities of $519.8M; cash runway to end-2026 unchanged.
FDA and EMA back MoonLake's Phase 3 program for sonelokimab in psoriatic arthritis
FDA and EMA unanimously supported MoonLake's proposed Phase 3 IZAR program for sonelokimab in PsA.
Director nominees Catherine Moukheibir (50.4M for) and Dr. Ramnik Xavier (53.9M for) elected; 4.24M broker non-votes.
MoonLake Q1 cash $547.1M; positive FDA/EMA feedback for Phase 3 sonelokimab in HS
Cash and equivalents $547.1M at March 31, 2024, expected to fund operations to end of 2026.
MoonLake reports 24-week PsA data with ~60% ACR50; plans Phase 3 HS trials in Q2 2024
ARGO trial: ~60% ACR50 at week 24; ~40% ACR70; >80% PASI90; ~60% PASI100; low discontinuation ~5%.
MoonLake FY 2023 net loss $44.1M; cash $511M; sonelokimab Phase 3 prep advances
Cash, cash equivalents and short-term marketable debt securities $511.0M at Dec 31, 2023, up from $496M at Sep 30, 2023.
MoonLake gets FDA & EMA support for Phase 3 sonelokimab in hidradenitis suppurativa
FDA and EMA both support Phase 3 design for sonelokimab (SLK) in HS; trial named VELA.
MoonLake Q3 cash $496M; positive Phase 2 data for sonelokimab in HS and PsA
Cash & equivalents $496.0M at Sept 30, 2023, expected to fund Phase 3 programs and regulatory filings.
MoonLake Phase 2 ARGO trial meets primary endpoint; sonelokimab ACR50 46-47% vs placebo
ACR50 achieved by 46% (60mg) and 47% (120mg) with induction at week 12 (p<0.01 vs placebo; ITT-NRI).
57% of patients on sonelokimab 120mg achieved HiSCR75 at week 24 (+10 ppt from week 12); 38% achieved HiSCR90 (+14 ppt).
MoonLake holds Capital Markets Day; posts investor presentation on website
Presentation posted September 11, 2023; covers financial position, near-term catalysts, and publication roadmap.
MoonLake raises CEO, CSO, CFO salaries and bonuses citing MIRA trial success
New annual base salaries July 1, 2023: CEO Jorge Santos da Silva CHF 600k (was CHF 450k), CSO Kristian Reich CHF 600k (was CHF 450k), CFO Matthias Bodenstedt CHF 475k (was CHF 325k).
MoonLake reports Q2 cash $501.8M after $460M offering; positive Phase 2 MIRA data in HS
Raised ~$460M gross in upsized public offering (8M shares at $50); cash & equivalents $501.8M at June 30, 2023.
MoonLake raises $460M in offering; Phase 2 MIRA trial meets primary endpoint with HiSCR75 at week 12
Priced 9.2M Class A ordinary shares at $50/sh (8M firm + 1.2M option) for $460M gross proceeds.
MoonLake's sonelokimab hits HiSCR75 with 29 ppt delta (p=0.0002) in Phase 2 HS trial
Primary endpoint HiSCR75 met with 29 ppt delta vs placebo (p=0.0002) at week 12.
MoonLake Immunotherapeutics announces 2023 AGM results; directors elected, auditor ratified
Dr. Kara Lassen elected as Class I director with 37,996,564 votes for, 93,222 withheld.
MoonLake Immunotherapeutics amends equity plans to provide automatic vesting upon change of control
Effective May 15, 2023, Board amended Employee Share Participation Plan and Stock Option Plan to include single-trigger vesting upon Change of Control.
MoonLake Immunotherapeutics posts Capital Markets Day presentation; no financial results disclosed
Presentation covers financial position, near-term catalysts, and publication roadmap.
Moonlake reports FY2022 net loss $64.5M; HS trial top-line expected June 2023
Net loss for year ended Dec 31, 2022 was $64.5M vs $53.6M for prior period (March 2021 to Dec 2021).
MoonLake Immunotherapeutics confirms no deposits or securities at SVB
Company aware of California regulator taking possession of Silicon Valley Bank.
MoonLake Immunotherapeutics dismisses Withum and engages Baker Tilly as auditor post-merger
Audit Committee dismissed WithumSmith+Brown as independent auditor effective June 15, 2022.
MoonLake posts Capital Markets Day presentation; no specific data disclosed in filing text
Company filed a Form 8-K announcing the posting of an investor presentation for Capital Markets Day on June 7, 2022.
Net loss of $15.88M for three months ended March 31, 2022; accumulated deficit of $69.5M.
MoonLake Immunotherapeutics (fka Helix Acquisition) closes business combination, lists on Nasdaq
Closed business combination Apr 5, 2022; Helix acquired MoonLake AG, renamed MoonLake Immunotherapeutics (MLTX).
Business Combination Agreement with MoonLake Immunotherapeutics AG approved; 11.5M votes for, 549K against.
Cormorant Asset Management LP, an affiliate of Helix officers, loaned $150,000 for working capital.
Helix enters $15M convertible loan with MoonLake; rollover option into PIPE
Cormorant Private Healthcare Fund IV lends MoonLake $15M interest-free, unsecured, for general corporate purposes pending business combination.
Helix Acquisition to restate financials after reclassifying all public shares as temporary equity
Non-reliance on previously issued financial statements from Oct 2020 through Sep 2021 due to share classification error.
Helix Acquisition Corp. announces business combination with MoonLake Immunotherapeutics; $115M PIPE
Helix (HLXA) to combine with MoonLake Immunotherapeutics AG, a Swiss immuno-dermatology biotech.
In connection with the Closing, Bihua Chen, Dr. Nancy Chang, Will Lewis and John Schmid resigned as directors of Helix, and Bihua Chen and Dr. Andrew J. Phillips resigned as officers of Helix.
In connection with the Closing, Bihua Chen, Dr. Nancy Chang, Will Lewis and John Schmid resigned as directors of Helix, and Bihua Chen and Dr. Andrew J. Phillips resigned as officers of Helix.
In connection with the Closing, Bihua Chen, Dr. Nancy Chang, Will Lewis and John Schmid resigned as directors of Helix, and Bihua Chen and Dr. Andrew J. Phillips resigned as officers of Helix.
In connection with the Closing, Bihua Chen, Dr. Nancy Chang, Will Lewis and John Schmid resigned as directors of Helix, and Bihua Chen and Dr. Andrew J. Phillips resigned as officers of Helix.
In connection with the Closing, Bihua Chen, Dr. Nancy Chang, Will Lewis and John Schmid resigned as directors of Helix, and Bihua Chen and Dr. Andrew J. Phillips resigned as officers of Helix.
In connection with the Closing, Bihua Chen, Dr. Nancy Chang, Will Lewis and John Schmid resigned as directors of Helix, and Bihua Chen and Dr. Andrew J. Phillips resigned as officers of Helix.
Max materiality 0.90 · Median 0.75 · Most common event other_material